DE602007013574D1 - Zusammensetzung mit mindestens einem Nukleosidteil als Heilmittel sowie CKC - Google Patents

Zusammensetzung mit mindestens einem Nukleosidteil als Heilmittel sowie CKC

Info

Publication number
DE602007013574D1
DE602007013574D1 DE602007013574T DE602007013574T DE602007013574D1 DE 602007013574 D1 DE602007013574 D1 DE 602007013574D1 DE 602007013574 T DE602007013574 T DE 602007013574T DE 602007013574 T DE602007013574 T DE 602007013574T DE 602007013574 D1 DE602007013574 D1 DE 602007013574D1
Authority
DE
Germany
Prior art keywords
composition
ckc
remedy
nucleoside part
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007013574T
Other languages
English (en)
Inventor
Gregory Lambert
Frederic Lallemand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novagali SA
Original Assignee
Novagali SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novagali SA filed Critical Novagali SA
Publication of DE602007013574D1 publication Critical patent/DE602007013574D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DE602007013574T 2007-11-14 2007-11-14 Zusammensetzung mit mindestens einem Nukleosidteil als Heilmittel sowie CKC Active DE602007013574D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07301550A EP2060262B1 (de) 2007-11-14 2007-11-14 Zusammensetzung mit mindestens einem Nukleosidteil als Heilmittel sowie CKC

Publications (1)

Publication Number Publication Date
DE602007013574D1 true DE602007013574D1 (de) 2011-05-12

Family

ID=39451279

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007013574T Active DE602007013574D1 (de) 2007-11-14 2007-11-14 Zusammensetzung mit mindestens einem Nukleosidteil als Heilmittel sowie CKC

Country Status (3)

Country Link
EP (1) EP2060262B1 (de)
AT (1) ATE503485T1 (de)
DE (1) DE602007013574D1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753270B2 (en) * 1998-05-21 2002-10-10 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
EP1469009A2 (de) 1998-05-21 2004-10-20 Isis Parmaceuticals, Inc. Zusammensetzungen und Verfahren für nicht-parenterale Verabreichung von Oligonukleotiden
US8168600B2 (en) 2004-04-23 2012-05-01 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
EP1891939B1 (de) * 2006-07-28 2013-09-11 Novagali Pharma S.A. Zusamensetzungen die quaternäre Ammonium Verbindungen enthalten

Also Published As

Publication number Publication date
EP2060262B1 (de) 2011-03-30
EP2060262A1 (de) 2009-05-20
ATE503485T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
CY1114979T1 (el) Συνθεσεις οι οποιες περιλαμβανουν ορνιθινη και φαινυλοξικο ή φαινυλοβουτυρικο για αντιμετωπιση ηπατικης εγκεφαλοπαθειας
BRPI0815322B8 (pt) "componente de conexão para respirador e máscara para proteção respiratória"
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
IL160420A0 (en) Treating or preventing diabetes with cannabidiol
WO2008041003A3 (en) Hydroxycholesterols and its prodrugs for the treatment of insulin resistance and disorers asociated therewith
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
UA94580C2 (ru) Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием
MY153408A (en) Novel methods
DK2219642T3 (da) Silibininbestandel til behandling af hepatitis
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
TW200740452A (en) Therapeutic gastrodia extracts
BRPI0713447A2 (pt) composição forma de dosagem oral sólida, e, método para o tratamento de dor
WO2009067397A3 (en) Treatment for solid tumors
HK1137352A1 (en) Therapeutic use of at least one botulic neurotoxin in the treatment of pain induced by at least one antineoplastic agent
DK1864668T3 (da) Anvendelse af prodrug til okulær, intravitreal administration
FR2899483B1 (fr) Dispositif de respiration artificielle pour patients atteints d'hypoxemie ou d'anoxemie
CY1110658T1 (el) Χρηση του καρραγηνου για τη θεραπεια μολυνσεων απο ρινοϊο
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"
WO2007135426A3 (en) Treatment of neurodegeneratives diseases
BRPI0806529A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta
DE602007013574D1 (de) Zusammensetzung mit mindestens einem Nukleosidteil als Heilmittel sowie CKC
DK1220676T3 (da) Forebyggelse af colorektal cancer
NO20091659L (no) Fremgangsmater for behandling av disruptive oppforselsforstyrrelser
WO2009063081A3 (en) Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc.